Kurin Jet
Prevention of Blood Culture Contamination
CommercialActive
Key Facts
About Kurin
Kurin is a commercial-stage diagnostics company addressing the costly and clinically significant problem of blood culture contamination. Its flagship product, the Kurin Lock integrated into a standard blood culture collection set, automatically diverts the initial 0.15ml of blood, which is most likely to contain skin microbes, without altering clinician workflow. The company is engaged in active litigation to defend its market position, has reported record revenue, and is scaling commercial operations. Kurin's value proposition centers on improving diagnostic accuracy, supporting antibiotic stewardship, and reducing unnecessary healthcare expenditures.
View full company profileTherapeutic Areas
Other Prevention of Blood Culture Contamination Drugs
| Drug | Company | Phase |
|---|---|---|
| Kurin Blood Culture Collection Set | Kurin | Commercial |
| Steripath Micro Commercialization & Evidence Generation | Magnolia Medical Technologies | Commercial |